Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nimotuzumab and Irinotecan in Solid Tumors
NCT02395068Phase 1Completed
- Start
- Dec 2012
- Primary completion
- Oct 2014
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of nimotuzumab in solid tumor (4 arms). Primary endpoint: Pharmacokinetics at 9 weeks. Started Dec 2012; status: completed.
02
Drugs
nimotuzumab
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02395068.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02395068.